Group 1 - The animal vaccine sector experienced a decline of 0.04%, ranking among the top losers in the concept sector, with notable declines from companies such as Hengtong Co., BioShares, and Kanghua Bio [1] - Among the animal vaccine stocks, 9 companies saw price increases, with Dongfang Bio, KQ Bio, and Haili Bio leading the gains at 2.23%, 0.87%, and 0.77% respectively [1] - The sector faced a net outflow of 212 million yuan from main funds, with 14 stocks experiencing outflows, and 7 stocks seeing outflows exceeding 10 million yuan, led by Roniu Mountain with a net outflow of 82.38 million yuan [2] Group 2 - The top stocks with net outflows included BioShares, Hengtong Co., and Kanghua Bio, with net outflows of 41.91 million yuan, 41.77 million yuan, and 24.74 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Dabeinong, Haili Bio, and Guoyao Modern, with net inflows of 32.76 million yuan, 6.20 million yuan, and 3.24 million yuan respectively [2] - The trading data indicated that Roniu Mountain had a trading rate of 8.05% and a price drop of 1.05%, while Dongfang Bio had a trading rate of 1.46% and a price increase of 2.23% [3]

Group 1 - The core point of the news is that Qingdao Weilan Biological Co., Ltd. experienced a stock price increase of 5.02%, reaching 15.06 CNY per share, with a total market capitalization of 3.811 billion CNY [1] - The company, established on February 23, 2005, specializes in the research, production, and sales of enzyme preparations, microecology, and animal health products [1] - The revenue composition of the company includes enzyme preparations at 36.63%, animal health products at 22.60%, other businesses at 21.75%, microecology at 17.27%, and others at 1.76% [1] Group 2 - From the perspective of the top ten circulating shareholders, Guotai Fund holds a position in Weilan Biological, with its Guotai Zhongzheng Livestock Breeding ETF (159865) increasing its holdings by 673,200 shares, totaling 2.1108 million shares, which represents 0.83% of the circulating shares [2] - The Guotai Zhongzheng Livestock Breeding ETF (159865) was established on March 1, 2021, with a current scale of 6.097 billion CNY, and has recorded a year-to-date return of 0.4% [2] - The fund manager, Liang Xing, has a tenure of 9 years and 215 days, with the fund's total asset size at 30.617 billion CNY, achieving a best return of 1112.34% during the tenure [3]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-057 青岛蔚蓝生物股份有限公司 关于公司 2026 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 12 月 26 日，公司召开第五届董事会第二十二次会议，审议通过了 《关于预计公司 2026 年度日常关联交易的议案》。根据《上海证券交易所股票上 市规则》《青岛蔚蓝生物股份有限公司章程》等的相关规定,公司无关联董事需对 本议案回避表决，所有董事一致同意通过该议案，且该议案无需提交公司股东会 审议。 （二）2025 年度日常关联交易预计和执行情况 2024 年 12 月 27 日，公司分别召开第五届董事会第十五次会议和第五届监 事会第九次会议，审议通过了《关于预计公司 2025 年度日常关联交易的议案》， 对公司 2025 年度日常关联交易情况进行了预计。2025 年度日常关联交易预计和 执行情况详见下表： 是否需要提交股东会审议：否 日常关联交易对上市公司的影响：本次日常关联交易预计为青岛蔚蓝生 物股份有 ...

Core Viewpoint - The company announced the approval of the expected daily related transactions for 2026, which will not require shareholder meeting review [1] Group 1: Company Transactions - In the period from January to November 2025, the company sold products worth 8.0795 million yuan to Beidahuang Baoquanling Agricultural and Animal Husbandry Development Co., Ltd. and its subsidiaries, which is below the expected amount of 15 million yuan due to market conditions [1] - For 2026, the company anticipates sales of enzyme preparations and other products amounting to 15 million yuan, representing 1.23% of the same type of business [1] - The pricing for these transactions will be based on market prices, ensuring that the company's independence is not affected [1]

Group 1 - The company has signed a maximum guarantee contract with China Everbright Bank for a total guarantee amount of RMB 10 million for its wholly-owned subsidiary, Qingdao Kangdian Animal Pharmaceutical Co., Ltd. [1][5] - The guarantee was approved by the company's board of directors on April 25, 2025, and subsequently by the annual shareholders' meeting on May 16, 2025 [2][6] - The guarantee covers all debts, including principal, interest, penalties, and other related costs incurred by the subsidiary [3][5] Group 2 - The necessity of the guarantee is justified as it supports the subsidiary's business development and operational needs, aligning with the company's overall interests and strategic development [6] - The subsidiary has a debt-to-asset ratio below 70%, allowing the company to effectively control operational risks and decision-making [6] - As of the announcement date, the total amount of external guarantees provided by the company and its subsidiaries is RMB 1.2302 billion, which accounts for 70.79% of the audited net assets attributable to shareholders as of December 31, 2024 [6][7]

Group 1 - The company announced that it will provide a joint liability guarantee of 10 million yuan for its wholly-owned subsidiary, Qingdao Kangdian Animal Pharmaceutical Co., Ltd., on December 24, 2025 [2] - As of the announcement date, the total amount of external guarantees provided by the company and its controlling subsidiaries is 123.02 million yuan, which accounts for 70.79% of the company's most recent audited net assets [2] - There are no overdue guarantees reported by the company [2]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-056 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 本次担保金额 | 实际为其提供的 | 是否在前期预计 | 本次担保是否有 | | --- | --- | --- | --- | --- | | | | 担保余额（不含本 次担保金额） | 额度内 | 反担保 | | 青岛康地恩动物药 业有限公司 | 1,000.00 万元 | 6,026.42 万元 | 是 | 否 | | 对外担保逾期的累计金额（万元） | 0.00 | | --- | --- | | 截至本公告日上市公司及其控股 | 123,020.00 | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 70.79% | | 特别风险提示（如有请勾选） | 担保金额（含本次）超过上市公司最近一 | | | 期经审计净资产 5 ...

Core Viewpoint - The company has obtained a new veterinary drug registration certificate for a trivalent inactivated vaccine targeting Newcastle disease, avian influenza (H9 subtype), and avian adenovirus disease (I group 4) [1] Group 1: Regulatory Compliance - The vaccine registration is in accordance with the Veterinary Drug Management Regulations and the Measures for the Approval Number Management of Veterinary Drug Products [1] - The company is currently in the process of applying for the veterinary product approval number issued by the Ministry of Agriculture and Rural Affairs, which is required before the product can be marketed [1]

Core Insights - The avian influenza concept sector experienced a decline of 0.76%, ranking among the top losers in the market, with major stocks like Zhongsheng Pharmaceutical hitting the limit down, while a few stocks like Wens Foodstuff and Weilan Biology saw gains of 1.80% each [1][2] Market Performance - The top-performing concept sectors included Titanium Dioxide with a gain of 4.31%, and Hainan Free Trade Zone with a gain of 3.54%, while the avian influenza sector was among the worst performers [1] - The avian influenza sector saw a net outflow of 784 million yuan, with 18 stocks experiencing net outflows, led by Zhongsheng Pharmaceutical with a net outflow of 684 million yuan [1] Stock Performance - Stocks with significant net outflows included: - Zhongsheng Pharmaceutical: -10.00% with a turnover rate of 18.78% and a net outflow of 683.65 million yuan - Yiling Pharmaceutical: -2.40% with a net outflow of 35.71 million yuan - Lianhuan Pharmaceutical: -1.79% with a net outflow of 25.69 million yuan - Hualan Biological: -6.60% with a net outflow of 18.13 million yuan [1] - Conversely, stocks with net inflows included: - Tiankang Biological: +1.26% with a net inflow of 16.52 million yuan - Shanghai Kaibao: -1.70% with a net inflow of 5.06 million yuan - Jinhai Biological: +0.16% with a net inflow of 3.82 million yuan [2]

Group 1 - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [1] - Anhui Construction won two major EPC projects with a total bid price of 2.603 billion yuan [2] - Tianrun Dairy's wholly-owned subsidiary received a government subsidy of 7.9094 million yuan, representing 18.12% of the company's audited net profit for 2024 [2] Group 2 - Yunnan Gold's subsidiary obtained a mining license for the Xinxiao County Tanxi Tungsten Mine, with a production capacity of 990,000 tons per year [5][22] - Yanzhou Coal Energy plans to acquire 100% equity of a high-end support company for 345 million yuan [6] - Heng Rui Pharmaceutical received approval for multiple drug clinical trials, including Sulfate Amexitin tablets [8] Group 3 - Huazhi Jie plans to invest 157 million yuan to establish five wholly-owned subsidiaries to expand its global strategy [1] - Junting Hotel's controlling shareholder is planning a change of control, leading to a continued suspension of trading [4] - Funi Technology's shareholder plans to reduce its stake by up to 1.68% [10] Group 4 - Midea Group's subsidiary received a government subsidy of 6 million yuan, which is 58.27% of the company's latest audited net profit [1] - Hunan Gold's subsidiary obtained a mining license for tungsten, iron, and silver, with a production scale of 990,000 tons per year [5][22] - Xin Hua Pharmaceutical received approval for the listing application of Acetate Prednisone raw material [24][25] Group 5 - Zhejiang Pharmaceutical plans to spin off its subsidiary for a listing on the Hong Kong Stock Exchange [28] - Kesheng Technology plans to invest 61.2 million yuan to acquire 51% of Shenzhen Guanding [30] - Tian Shan Aluminum's 1.4 million tons electrolytic aluminum green low-carbon energy efficiency improvement project has commenced production [38]